Research Article

Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy

Figure 3

Copper potentiation of low-dose disulfiram selectively targets K12 cells compared to K7M2 cells. Both K12 and K7M2 cells were subjected to fold dilutions of Dox (a), CuCl2 (b), or Dis (c) single agent treatment over 24 hours. Additionally, cells were treated with fold dilutions of Dis + CuCl2 at fixed concentrations of 50 nM (d), 200 nM (e), or 800 nM (f). After treatment, cells were stained with LIVE/DEAD stain, and microscopy images were obtained. Live signal reduction from untreated controls was analyzed using FIJI image mean fluorescence measurements. 50 nM CuCl2 significantly decreased the live signal % in K12 than in K7M2 from 80 nM to 2.5 μM dose of Dis. All cytotoxicity experiments were performed in technical triplicate with three separate cell cultures . .
(a)
(b)
(c)
(d)
(e)
(f)